Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiogenic Study of Everolimus in Metastatic Pancreatic NETs
NCT02305810Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Sep 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in Pancreatic neuroendocrine tumor (PanNET), sponsored by European Institute of Oncology. Started Sep 2013; status: completed.
02
Drugs
everolimus
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02305810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305810.